To the full analysis
GSK stock: growth
GSKGSK reported $43.3B in revenue for fiscal 2025, up 4.1% on the prior year, up 6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
1.8%
per year from 2006 to 2025, per share 2.4%
Earnings (Annual rate)
0.3%
per year from 2006 to 2025, per share 0.9%
Free cash flow (Annual rate)
3.7%
per year from 2006 to 2025, per share 4.3%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 6.0% | 3.2% | 1.8% |
| Revenue per share | 5.7% | 2.7% | 2.4% |
| Earnings | −0.1% | −3.8% | 0.3% |
| Earnings per share | −0.4% | −4.3% | 0.9% |
| Free cash flow | −6.0% | 21.7% | 3.7% |
| Free cash flow per share | −6.4% | 21.1% | 4.3% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $30.78B | $7.14B | $3.14B |
| 2007 | $30.14B | $6.92B | $4.84B |
| 2008 | $32.28B | $6.1B | $6.95B |
| 2009 | $37.6B | $7.33B | $7.91B |
| 2010 | $37.64B | $2.17B | $6.84B |
| 2011 | $36.3B | $6.97B | $6.52B |
| 2012 | $35.04B | $5.96B | $3.78B |
| 2013 | $35.13B | $7.21B | $7.32B |
| 2014 | $30.5B | $3.65B | $4.54B |
| 2015 | $31.71B | $11.16B | $885.47M |
| 2016 | $36.97B | $1.21B | $5.49B |
| 2017 | $40.01B | $2.03B | $6.25B |
| 2018 | $40.86B | $4.8B | $8.78B |
| 2019 | $44.74B | $6.16B | $7.76B |
| 2020 | $32.28B | $7.62B | $8.61B |
| 2021 | $32.74B | $5.81B | $7.02B |
| 2022 | $38.87B | $19.83B | $8.95B |
| 2023 | $40.2B | $6.53B | $5.86B |
| 2024 | $41.59B | $3.41B | $4.73B |
| 2025 | $43.3B | $7.58B | $6.3B |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = £0.7544)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 13 Nov 2026, previously Strong
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.